Health Canada Approves Optimi Health Precursor License to Formulate MDMA and Encapsulate Various Dosages
Optimi Health recently received a Precursor License to import the precursor of MDMA and encapsulate the drug into specific dosages.
In a recent press release, Optimi Health, “a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA,” (1) announced that they received a Precursor License for 3,4-Methylenedioxyphenyl-2-propanone (MDP2P) from Health Canada. This chemical compound is the predecessor to 3,4-Methylenedioxymethamphetamine (MDMA) (1).
Optimi Health gained their Precursor License back in December 2023 (1) through Section 16 of the Precursor Control Regulations. This access provides the drug researcher to “import MDP2P for the purpose of formulating and verifying MDMA drug candidates” at the their research and analytical facility located in Princeton, British Columbia, Canada (1). Health Canada had also toured the establishment recently.
“Securing our precursor licence represents a pivotal advantage for Optimi, offering a compelling edge in producing MDMA at significantly reduced costs,” Jacob Safarik, Optimi Chief Financial Officer, commented (1). “This strategic move aligns with our intent to address market demand for GMP MDMA in 2024, especially amid the heightened anticipation surrounding the recent New Drug Application (NDA) submission by the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC) to the U.S Food and Drug Administration (FDA).”
The Chief Financial Officer also mentioned a recent update stemming from the American Medical Association (1), “With the AMA’s current procedural terminology ("CPT") III codes for psychedelic-assisted therapies now officially in effect, this underscores the goal of obtaining our precursor license. With potential FDA approval, physicians and other qualified healthcare providers seeking coverage and reimbursement for delivering psychedelic-assisted therapy will now have a reliable partner who can formulate and encapsulate the most cost-effective, high-quality, and accessible MDMA solutions in the market.”
After obtaining the Precursor License, Optimi Health was able to encapsulate MDMA into two dosage formats, 40mg and 60mg (1). “This milestone is more than formulation. It symbolizes our dedication to achieving scientific uniqueness in alliance with industry pioneers such as the MAPS PBC who are paving the road ahead,” Dr. Preston A. Chase said (1). “Our innovation journey is grounded in advancing the safety and validity of our MDMA drug candidate, and I am happy to say that we’re just hitting our stride in becoming the premier provider of fully verified, encapsulated MDMA in 2024 and beyond.”
In one of the last developments Optimi Health disclosed in their press release (1) is that they are working on being granted a Certificate of Analysis (COA) from a third-party laboratory which will help provide their clients with further assurance.
Reference
- Optimi Health Corp. Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats https://www.globenewswire.com/news-release/2024/01/03/2803195/0/en/Optimi-Health-Granted-Precursor-Licence-To-Formulate-MDMA-And-Completes-Encapsulation-Of-40mg-And-60mg-Dosage-Formats.html (accessed Jan 3, 2024).
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
